Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.48 |
| ▸ | PYGM | P11217 | 12/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440435 | 0.88 | PYGL (0.51) | PYGLPYGMTDP1L3MBTL1RXFP1 | |
| SCHEMBL6433335 | 0.87 | PYGL (0.62) | PYGLPYGMTDP1L3MBTL1RXFP1 | |
| SCHEMBL6701597 | 0.84 | KDM4E (0.47) | PYGLPYGMTDP1L3MBTL1RXFP1 | |
| SCHEMBL6440425 | 0.83 | L3MBTL1 (0.50) | PYGLPYGMTDP1L3MBTL1RXFP1 | |
| SCHEMBL6435759 | 0.78 | PYGL (0.55) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL6431607 | 0.76 | PYGL (0.68) | PYGLPYGMTDP1L3MBTL1 | |
| SCHEMBL6432016 | 0.76 | L3MBTL1 (0.61) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL6431814 | 0.75 | PYGM (0.61) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL7126723 | 0.75 | PYGL (0.66) | PYGLPYGMTDP1KDM4E | |
| SCHEMBL6431424 | 0.74 | PYGL (0.74) | PYGLPYGMTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | PYGL 4/4885PYGM 1/4885TDP1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.